Moreover, in vivo cotreatment with curcumin and gemcitabine significantly reduced tumor size and growth rate, as well as LAT2 expression in a gemcitabine-resistant CCA xenograft mouse model. Here, LAT2 is linked to cholangiocarcinoma.